Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications
James S. J. Manuso - Chairman of The Board and Chief Executive Officer
Astex Pharmaceuticals, Inc. (ASTX) Acquisition by Otsuka Pharmaceutical Company Conference September 5, 2013 8:00 AM ET
Good day, ladies and gentlemen, and welcome to the Astex Pharmaceuticals Corporate Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference, Tim Enns, Senior Vice President of Corporate Communications and Marketing. You may begin.
Timothy L. Enns
Thank you, operator. Good day, and thank you for joining us for this Astex Pharmaceuticals Corporate Conference Call. With me today is Dr. James Manuso, Chairman and Chief Executive Officer. Earlier today, we issued a press release announcing Otsuka Pharmaceutical Co., Ltd.'s agreement to acquire Astex Pharmaceuticals and commence a tender offer. A copy of the press release and a link to the webcast of this call is available in the Investor Relations section of our website at www.astx.com. A webcast replay will be available for 7 days at the same site.
The tender offer for the outstanding shares of Astex has not yet commenced. This communication is provided for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of Astex pursuant to the tender offer by Autumn Acquisition Corporation, a wholly-owned subsidiary of Otsuka, or otherwise. Any offer to purchase or solicitations to offer to sell will be made only pursuant to the tender offer statement on Schedule TO, including the offer to purchase the letter of transmittal and other documents relating to the tender offer, which will be filed with the U.S. Securities and Exchange Commission by Otsuka and sub -- acquisition sub. In addition, Astex will file with the SEC a solicitation recommendation statement on Schedule 14D-9 with respect to the tender offer.
Astex shareholders are advised to read these documents, any amendments to these documents and any other documents related to the tender offer that are filed with the SEC carefully and in their entirety prior to making any decision with respect to the acquisition sub's tender offer because they contain important information, including the terms and conditions of the offer. Astex stockholders may obtain copies of these documents when they become available for free at the SEC's website at www.sec.gov.
During this call, we will make projections and forward-looking statements that are based on management's current expectations. These forward-looking statements include statements regarding the satisfaction of conditions to the completion of the proposed transaction and the expected completion of the proposed transaction, as well as other statements that are not historically fact. These forward-looking statements are based on currently available information, as well as Astex's views and assumptions regarding future events at the time those such statements are being made. Such forward-looking statements are subject to the inherent risks and uncertainties.
Accordingly, actual results may differ materially from those expressed or implied in such forward-looking statements. Such risks and uncertainties include, but are not limited to, the potential failure to satisfy conditions for the completion of the proposed transaction due to the failure to receive a sufficient number of tendered shares in the tender offer. As a result of these and other risks, the proposed transaction may not be completed on the time frame expected or at all. The company's results may also be affected by a variety of factors such as competitive developments, launches of new products, the timing of anticipated regulatory approvals or other regulatory action, the action of our strategic partners and collaborators with respect to the products we license or codevelop and patent disputes and litigation. For additional information and discussions concerning these risk factors that affect the company's business, please refer to the company's filings with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements.
I will now turn the call over to Dr. James Manuso, who will discuss today's announcement. Jim?
James S. J. Manuso
Thank you, Tim. Good morning, and thank you for joining this Astex Pharmaceutical's Corporate Conference Call. Today's announcement outlined Otsuka Pharmaceutical Co., Ltd.'s agreement to acquire Astex Pharmaceuticals, Inc. for $8.50 per fully diluted share in cash, for a total consideration of approximately $886 million calculated using the treasury stock method. This represents a 48% premium over the 30-day average closing price of our stock, ASTX, on the NASDAQ exchange. The boards of both companies approved the agreement and plan of merger.
The next step will be the commencement of a tender offer by Otsuka to all Astex stockholders. Pending acceptance of the offer by stockholders holding a majority of our common stock and the fulfillment of other customary closing conditions, the transaction is expected to close in the fourth quarter of 2013.
Under the terms of the transaction, Astex is expected to remain substantially intact and become a wholly-owned subsidiary of Otsuka. The process that led to this definitive offer from Otsuka started with the completion of an internal 5-year business plan review that included exploration of the sale of the company. As a result of this review, a subcommittee for strategic planning was appointed by the board. I chaired this subcommittee composed of 3 of our independent directors, including Vice Chairman, Dr. Peter Fellner; Lead Director, Walter Lack; and Charles Casamento. The subcommittee was tasked with interviewing and selecting a banker to advise and represent us in the process of assessing and contacting parties that might be interested in purchasing the company.
Jefferies was retained as the sole financial advisor, and a competitive marketing process was conducted to find a buyer that would recognize the value of our pipeline, discovery process, development capability and people. Naturally, we sought interested parties who had the financial and infrastructural resources to offer the most competitive price for Astex and enhance and expand our overall development and discovery capabilities to permit us the potential of delivering promising medicines to patients.
Many companies were contacted confidentially and offered the opportunity to learn more about our company as a prelude to a sale, and Otsuka emerged as the highest bidder interested in acquiring Astex. We believe this transaction with Otsuka is an excellent path to leverage the full potential and value of Astex's clinical assets and its world-class drug discovery capabilities. Our assets include our prioritized products, SGI-110, AT13387 and AST727 (sic) (ASTX727), in addition to the PYRAMID drug discovery platform, a platform that has delivered 8 INDs in 8 years.
As I indicated earlier, upon the close of this transaction, Astex will become a wholly-owned subsidiary of Otsuka. Otsuka management have indicated that the intention is to retain Astex's existing infrastructure and organization in the U.S. and U.K. as is. As Dr. Taro Iwamoto, Otsuka Pharmaceutical's President and Representative Director, stated in today's press release, and I quote, "I hope that this transaction -- this acquisition of Astex will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field through the acquisition of Astex's fragment-based drug design technology at its Cambridge, England research headquarters and its California clinical oncology R&D department. I would like Otsuka Pharmaceutical to continue to respect Astex's uniqueness and leverage it to bring further growth for Otsuka Pharmaceutical." Until the transaction closes, no changes will be made to current Astex clinical development or discovery programs. SGI-110 and other preclinical and clinical data will continue to be presented at upcoming scientific conferences this year as we have previously outlined.
Thank you again for joining us for today's call, and thank you for your many years of support that permitted us to build and grow a highly valued company. The Astex management team, the board, and I look forward to updating you on our progress, and we wish you a pleasant day. Thank you.
Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.org. Thank you!